Delayed Generic Market Saturation After Patent Expiration-A Billion-Dollar Problem
JAMA Intern Med
.
2018 May 1;178(5):721-722.
doi: 10.1001/jamainternmed.2018.0989.
Authors
Jing Luo
1
,
Aaron S Kesselheim
1
Affiliation
1
Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
PMID:
29801126
DOI:
10.1001/jamainternmed.2018.0989
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Atorvastatin
Drugs, Generic*
Economic Competition
Health Expenditures*
Substances
Drugs, Generic
Atorvastatin